Adolor Corporation (ADLR) and GlaxoSmithKline (GSK) have jointly announced that the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review Adolor’s application for the new drug, Entereg. This drug can accelerate the time it takes for pain to dissipate after large or small bowel resection surgery with minimal intrusion.

Adolor Corporation (ADLR) is a biopharmaceutical company specializing in the discovery, development, and commercialization of pain management products. Adolor has a large number of discovery and clinical research programs that are focused on the various treatments of pain. Adolor is seeking to make a positive difference on patients, caregivers, and the medical community by reducing pain in the most common procedures.

GlaxoSmithKline is the world’s leading research-based pharmaceutical and healthcare company, focused on improving the quality of human life by enabling people to do more, feel better and live longer.

Let us hear your thoughts below: